AstraZeneca hails gefurulimab trial results on myasthenia gravis
(Alliance News) - AstraZeneca PLC on Thursday said its investigational complement C5 inhibitor gefurulimab showed statistically significant results in treating adults with a form of generalised myasthenia gravis, an autoimmune neuromuscular disease. Read More